abstract |
Embodiments of the present invention provide antibodies, antigen binding portions thereof, and other polypeptides (e.g., CARs), that specifically bind to CSPG4, an antigen expressed on cancer cells. Monoclonal antibodies, antibody-drug conjugates, and/or CAR-T-cells that specifically bind to CSPG4 positive cancer cells are also provided. |